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BASICS
DESCRIPTION
• From the Latin, hirsutus = hairy
• Symptom associated with male pattern of
pigmented terminal hair growth
Locations are assessed for research purposes in
Ferriman-Gallwey score.
• Often associated with acne, irregular menstrual
periods, galactorrhea, dark velvety patches of skin,
central obesity, infertility

Pediatric Considerations
Infancy to late childhood (< 10 years of age):
Associated with Cornelia de Lange syndrome, FAS,
CAH, adrenocortical tumors, or drug-induced
., Adolescence: Associated with PCOS, late-onset
CAH, HAIR-AN syndrome, steroid use, depression,
pregnancy, or drug-induced
Adulthood: Associated with PCOS, HAIR-AN
syndrome, hyperprolactinemia, ovarian tumor,
menopause, depression, or drug-induced
EPIDEMIOLOGY
5- 10% of women, of which 20% have idiopathic
hirsutism
RISK FACTORS
Ethnicity (Mediterranean, Middle Eastern, South
Asian)
• Family history
• Infertility
• Obesity

Genetics
Can be familial or multifactorial
' Seen with:
- Polymorphism of 5 a-reductase (SRD5A 1 and
SRD5A2) isomers
- CYP21 gene mutation
- NIPBL mutation associated with Cornelia de
Lange syndrome
PATHOPHYSIOLOGY
• Caused by increased:
- Levels of androgen secretion (DHEA, DHEAS,
androstenedione and testosterone)
- Peripheral conversion of testosterone to potent
DHT
-Sensitivi ty of hair follicles to androgens regulated
by 5 a-reductase, which transforms testosterone
or androstenedione to DHT
• Caused by decreased:
- SHBG concentration with resultant increased free
androgen

ASSOCIATED CONDITIONS
'" Idiopathic hirsutism
• PCOS
• HAIR-AN syndrome
• CAH
• Cushing disease
• Hyperthecosis
• Hypothyroidism
• Hyperprolactinemia
• Adrenocortical tumors
• Ovarian tumors
• Cornelia de Lange syndrome
• Fetal alcohol syndrome
• Drugs: Corticosteroids, anabolic steroids, phenytoin,
valproate, danazol, diazoxide, minoxidil
• Pregnancy
• Stress
• Male pseudohermaphroditism
• Depression

DIAGNOSIS
SIGNS AND SYMPTOMS
• Based on the Ferriman-Gallwey score of hair growth
level on 9 different locations of the body:
-Upper lip, chin, chest, upper back, lower back,
upper abdomen, lower abdomen, upper arms, and
thighs
- Hair growth is rated from 0- 4, where 0 is virtually
no hair at all, and 4 is completely covered with
hair. The maximum score is 36. Commonly used
research scale in US
-Normal: < 8
o Light hirsutism: 8-16
o Moderate hirsutism: 17-25
o Severe hirsutism: >26
• The scale may vary for different ethnic groups with
different levels of expected hair growth.

History
' Age of onset
• Duration
• Location
• Rate of progression
• Skin changes
• Associated symptoms of virilization
' Medication use
• Ethnic background
• Medical history
• Puberty/Menstrual history
• Family history of females with hirsutism, males with
early balding
• Psychosocial history/stress, depression

Review of Systems
Other associated signs and symptoms:
• Acne
• Irregular menstrual periods ,'<''
• Dark velvety patches of skin1acanthosis nigricans)
• Breast disch~rge
• Central obesity
• Deepening of the voice
• Increased muscle mass
• Infertility
Physical Exam
• Vitals: Increased BMI, high BP, waist circumference
> 30 inches
• General: Central obesity, BMI, dysmorphism,
deepening of voice, male habitus
• Skin: Acne, male pattern hair, seborrhea
• HEENT: Tonsillar enlargement, thyromegaly,
acanthosis nigricans, cervical fat pad, temporal
balding
• Chest: Breast tenderness, galactorrhea, truncal
obesity, buffalo hump
• Abdomen: Striae, tenderness
• GU: Clitoromegaly, ovarian mass
TESTS
Ferriman-Gallwey scoring for research purposes

Labs
Testing as clinically appropriate for:
• DHEA-S
• Total testosterone
• Free testosterone
• Fasting Insulin and glucose
• IGF-1
• TSH
• Free T4
• 17 OH progesterone
• Prolactin
• LH
• FSH
• ACTH
• Cortisol
• 24-hour urine cortisol
Imaging
• Pelvic ultrasound if ovarian mass suspected
• CT abdomen and pelvis if adrenal mass suspected
• MRI head if pituitary abnormality suspected
DIFFERENTIAL DIAGNOSIS
• Hypertrichosis: Excessive androgen-independent fine
and soft total body hair growth in both men and
women
• Idiopathic hirsutism

MEDICATION (DRUGS)
Aimed at primary cause of hirsutism:
OCP reduces circulating androgen levels through
suppression of circulating LH, stimulation of SHBG
levels with resultant decreases in free androgens,
and reduction of Sa-reductase activity
Clomiphene induces ovulation
Metformin promotes ovulation and reduces insulin
resistance of peripheral tissue.
Gonadotropins: Leuprolide
Cyproterone competes with DHT for binding to the
androgen receptor.
Spironolactone competes with DHT for binding to
the androgen receptor.
Flutamide is a pure androgen receptor blocker.
Ketoconazole reduces levels of concentration of
circulating androgens.
Finasteride inhibits activity of Sa-reductase,
SURGERY
Hair removal with intense pulsed light irradiator
system (IPL) or normal-mode ruby laser for
idiopathic or familial hirsutism
Surgery can be aimed at underlying pathology:
-Adrenal/Ovarian tumor resection
-Oophorectomy for androgen-producing ovarian
tumor
-Ovarian wedge resection/ovarian drilling in PCOS
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FOLLOW-UP
;/

Depends on cause or associated condition
DISPOSITION
Issues for Referral
Endocrinology or gynecology or genetics or surgery
for hormonal or syndromic or tumor etiology
Dermatology or cosmetology for idiopathic or
familial hirsutism only
PROGNOSIS
Dependent on cause and intervention or therapy

increase rate of hair growth.

PATIENT MONITORING
Endocrinology or gynecology or genetics or surgery
for hormonal or syndromic or tumor etiology
Dermatology or cosmetology for idiopathic or
familial hirsutism only
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MISCELLANEOUS
Virilization indicates more severe androgen effect
including breast atrophy, clitoromegaly, temporal
balding
CLINICAL PEARLS
Hirsutism without menstrual irregularities or weight
gain is most likely idiopathic or familial.
Adolescents with hirsutism and early-onset, severe,
and refractory acne are likely to have PCOS; OCPs
can benefit self-esteem and prevent scarring from
acne.
Hirsutism can be the only clinical presentation of
depression or stress in adolescents; warrants
psychosocial workup.
ABBREVIATIONS
ACTH-Adrenocorticotropic hormone
CAH-Congenital adrenal hyperplasia
DHEAIDHEAS-Dehydroepiandrosterone-DHEAS
sulfate
DHT-Sa-dihydrotestosterone
FAS-Fetal alcohol syndrome
FSH-Follicular stimulating hormone
HEENT-Head, eyes, ears, nose, throat exam
IGF-1-Insulin-like growth factor
·
LH-Luteinizing hormone
OCP-Oral contraceptive pill
PCOS-Polycystic ovarian syndrome
SHBG-Sex hormone binding globulin
TSH-Thyroid stimulating hormone
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Diagnosis of idiopathic hirsutism or familial hirsutism
should be considered after a thorough workup for
all other causes such as hormonal, oncologic, and
syndromic agents have been ruled out.
Current medical therapies have their pros and cons.
No drug is yet FDA approved. Cosmetic remediation
or counseling and education may also be helpful.

PREVENTION
Exercise for weight control and stress reduction may
improve PCOS.
Careful use of medication such as steroids,
antiepileptics, vasodilators with awareness of
hirsutism as side effect

